These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of mucopolysaccharidosis type IVA (MPS IVA) through the LSDP
- Drugs currently available for the treatment of MPS IVA through the LSDP
- Dosage
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Guidelines
About this resource
Publication date:
Publication type:
Guideline
Language:
English
Part of a collection: